OncoGenex Pharmaceuticals (OGXI) today announced that it has restated its financial results for the first quarter of 2014.  The company's first quarter 2014 financial results were announced on April 30, 2014.  The company's CEO Cheryl Cormack and CFO, Filippo Petti, announced the results of a clinical trial that evaluated the effectiveness of custirsen in combination with cabazitaxel, a second-line chemotherapy, in approximately 630 men with advanced bladder cancer.  The results of the trial were unexpected, given the large amount of preclinical and clinical evidence confirming custirsen's ability to suppress the cancer-protective protein, clusterin, and for long overall survival.  The company's continuing to pursue this approach through the ongoing development of custirsen and apatorsen.  Cheryl Cormack and Filippo Petti will lead the call.  The company's Investor Day is April 30, 2014.  The SEC encourages investors to check the backgrounds of people selling them investments by using theÂ SECÂ Investor.govÂ to quickly identify whether they are registered professionals.  The SECÂ also encourages investors to check the backgrounds of people selling investments by using the SECÂ Investor.govÂ Investor.govÂ to identify whether they are registered professionals.